Bcl10 was identi®ed as a candidate gene responsible for low grade B cell lymphomas of mucosa-associated lymphoid tissue. Overexpression of Bcl10 in cultured cells was reported to promote apoptosis, however, the mechanism of regulation of apoptosis mediated by Bcl10 has not been demonstrated. In the present study, we analysed the apoptosis signaling pathway mediated by Bcl10, focusing on phosphorylation of Bcl10 and the dynamic interaction with its binding partners during apoptosis. Previously, we have demonstrated that Bcl10 potentially interacts with the other apoptosis regulator, TNF receptor associated factor-2 (TRAF2) and inhibitor of apoptosis proteins (cIAPs). The present results showed that the complex formation of these molecules was regulated by phosphorylation of Bcl10, that is, phosphorylation of Bcl10 resulted in binding of Bcl10 to cIAPs and the dissociation of it from TRAF2. Moreover, hyperphosphorylation of Bcl10 enhanced apoptosis, suggesting that changes in the binding partners of Bcl10 were correlated to the promotion of apoptosis as mediated by Bcl10. Indeed, the mutant which was deleted from the binding site of Bcl10 for cIAPs, could not induce apoptosis. These ®ndings indicate that Bcl10 is a mediator of apoptosis signaling, by switching over binding to cIAPs from TRAF2 through the events of Bcl10 phosphorylation. Oncogene (2001) 20, 4317 ± 4323.
Introduction
It is well known that recurrent chromosome 1p22 abnormalities occur in several types of lymphoma, however, the molecular events remain unsettled.
Recently, Bcl10 has been identi®ed as a mutative gene with high frequency chromosomal translocation t(1;14)(p22;q32) (Willis et al., 1999; Zhang et al., 1999) , suggesting that it is a target gene involved in the pathogenesis of a wide range of human malignancies (Bertoni et al., 1999; Du et al., 2000; Simms et al., 2000; Yamamoto et al., 2000) . Bcl10 has a caspaserecruiting domain (CARD) at its amino-terminal region. The CARD domain is suggested as mediating the binding between adapter molecules and caspases. The domain is found in a number of components of apoptosis cascades such as pro-apoptotic RAIDD/ CRADD, RIP2/CARDIAK, Ced4/Apaf-1 and antiapoptotic cIAP1, cIAP2 and ARC (Cecconi, 1999; Chou et al., 1998; Koseki et al., 1998; McCarthy et al., 1998; Rothe et al., 1995) . Recently identi®ed protein, CARD9, binds to Bcl10 and induces NFkB activation (Bertin et al., 2000) . These CARD-containing proteins interact with each other under a variety of stimuli, including DNA-damaging agents, growth factor starvation and treatment of cell-death ligands such as Fas and TNF. The resultant bindings cause activation of downstream signaling, initiating apoptosis (review by Homan et al., 1997; Hofmann, 1999) .
Previously, we have reported that Bcl10 binds to both TNF receptor associated factor-2 (TRAF2) and inhibitors of apoptosis proteins (cIAPs), which form TNF-receptor complexes (Yoneda et al., 2000) . It is well known that TRAF2 mediates signaling via TNFreceptors and is mainly involved in NF-kB activation (Arch et al., 1998) . The activation of NF-kB promotes the expression of genes encoding anti-apoptotic factors that allow the cell to survive. One of these inducible genes is cIAP2 which can be a potent inhibitor of active caspases, and also activates NF-kB (Rothe et al., 1995; Shu et al., 1996; Wang et al., 1998) . Taken together, Bcl10 could play a role in apoptosis by regulating the interaction with TRAF2 or cIAPs.
In the present study, we examined the mechanisms responsible for interaction of these three molecules, and demonstrated that the interaction could be regulated by alteration of phosphorylated-Bcl10. We also showed that a combination of interaction with cIAP2 and dissociation from TRAF2 is necessary for apoptosis mediated by Bcl10.
Results

Regulation of Bcl10 phosphorylation
Western blotting of Bcl10 in cells in which its expression plasmids were introduced showed a 32 ± 35 kDa double band (Figure 1) , and the higher band of 35 kDa was demonstrated, by metabolic labeling experiments using 32 P, to be phosphorylated Bcl10 (data not shown). The ®nding raised the possibility that the function of Bcl10 may be regulated by its phosphorylation. First, we examined the eects of various agents for protein kinase activators and inhibitors on Bcl10 phosphorylation. We treated 293T cells transiently transfected with Bcl10 expression plasmids with ®ve kinds of agents, 10 nM phorbol 12-myrisate 13-acetate (PMA) (activator of protein kinase C(PKC)), 10 mM H-7 (inhibitor of PKC), 10 mM Forskolin (activator of adenylate cyclase and increases cytosolic cyclic-AMP), 10 mM H-89 (inhibitor of protein kinase A(PKA)) and 1 mM Wortomaninn (inhibitor of PI3 kinase). The levels of phosphorylated Bcl10 were markedly increased by treatment with PMA and decreased by H-7. Phosphorylation of Bcl10 was also promoted by treatment with Forskolin, and slightly inhibited by Wortomaninn. Treatment with H-89 did not aect Bcl10 phosphorylation (Figure 1 ). These results indicated that regulators of PKC activities eectively altered the levels of phosphorylated Bcl10, however, as some other kinase modulators also aect those, it is still unclear whether Bcl10 is phosphorylated by PKC directly or indirectly. From this data, we used PKC modulators to regulate the levels of Bcl10 phosphorylation in the following experiments.
Bcl10 phosphorylation and apoptosis
Overexpression of Bcl10 has been known to induce apoptosis in 293T cells. To examine the eects of phosphorylation of Bcl10 on apoptosis signaling, 293T cells, which were beforehand transfected with Bcl10 expression plasmids, were treated with PMA and H-7. Treatment with PMA signi®cantly enhanced activities of caspase-3 like proteases twofold compared with the controls, which were not treated with PMA ( Figure  2a) . Morphologically, we con®rmed that cell death induced by overexpression of Bcl10 was promoted by treatment with PMA ( Figure 2b ). Conversely, treatment with H-7 inhibited activation of caspase-3 like proteases and cell death induced by Bcl10. Neither PMA nor H-7 aected the viabilities in non-transfected 293T cells, and also did not cause changes in the expression levels of Bcl10 (data not shown), suggesting that phosphorylated forms of Bcl10 could contribute to activation of Bcl10-mediated cell death.
Phosphorylation of the endogenous Bcl10
Bcl10 is highly expressed in lymphoid tissues (Willis et al., 1999; Yoneda et al., 2000) . From our previous observation of remarkable atrophy of the thymus in Bcl10 overexpressed mice, we used thymocytes as a model to monitor the endogenous Bcl10 phosphorylation followed by cell death. Thymocytes were metabolically labeled by 32 P for 3 h, and immunoprecipitated with anti-Bcl10 polyclonal antibody. After treatment with PMA, the endogenous Bcl10 phosphorylation level was signi®cantly increased compared with the Figure 1 Eects of various agents which activate or inhibit protein kinases on phosphorylation of Bcl10. Western blotting analyses were performed with anti-Bcl10 antibody using cell lysates expressing Bcl10 after treatment with the indicated agents for 30 min. Signal intensities for phosphorylated forms of Bcl10 were measured using a densitometer. A value of 1.0 corresponds to the amount of phosphorylated Bcl10 protein in unstimulated cells. Data from four independent measurements are plotted as relative density. P-Bcl10; Phosphorylated Bcl10 control, which is not treated with PMA ( Figure 3a ). We also con®rmed that the treatment with PMA caused DNA fragmentation and cell death ( Figure  3b ,c) as previously reported (Kizaki et al., 1989) . Taken together, endogenous Bcl10 is indeed phosphorylated in thymocytes during apoptosis induced by PMA and the ®ndings lead us to speculate that the phosphorylation of Bcl10 might be playing crucial roles in apoptosis signaling in thymocytes.
Dynamic interaction of Bcl10 with TRAF2 or cIAP2
In our previous paper we reported that Bcl10 binds to both TRAF2 and c-IAPs (Yoneda et al., 2000) , suggesting that these proteins could be involved in modulation of Bcl10 functions through direct interaction. We examined whether phosphorylation of Bcl10 altered the complex formation of Bcl10, TRAF2 and cIAPs. After treatment with 10 nM PMA, or 10 mM H-7 for 6 h, cells were lyzed and immunoprecipitated with anti-Bcl10 polyclonal antibody, followed by immunoblotting with anti-TRAF2 or anti-cIAP2 polyclonal antibodies. Treatment with PMA decreased amounts of TRAF2 co-immunoprecipitated with Bcl10 (Figure 4a ), alternatively, it increased those of cIAP2 bound to Bcl10 (Figure 4b ). In contrast, treatment with H-7 enhanced both interactions of Bcl10 with TRAF2 and dissociation of Bcl10 from cIAP2 (Figure 4a,b) . The same results were obtained in the reverse experiments, which were immunoprecipitated with anti-TRAF2 or anti-cIAP2 polyclonal antibodies, followed by immunoblotting with anti-Bcl10 antibody. We also tested that the co-treatment of cells with H-7 and PMA reverses the eects of PMA on phosphorylation and binding of Bcl10 to cIAP2 (data not shown). In all these experimental conditions, expression levels of TRAF2 and cIAP2 were not changed (Figure 4a,b) . These ®ndings suggest that the changes in phosphorylation of Bcl10 may alter its binding partners, that is, phosphorylated forms of Bcl10 interact with cIAP2, and non-phosphorylated-forms interact with TRAF2.
Functional domains in Bcl10
As described above (Figure 4) , the phosphorylated form of Bcl10 interacts with cIAp2 during apoptosis induced by overexpression of Bcl10. To examine the binding site of Bcl10 to cIAP2, we engineered ®ve deletion mutants, delta C143 (amino acids 1 ± 143), delta C191 (1 ± 191), delta N48 (48 ± 233), delta N78 (78 ± 233) and delta N117 (117 ± 233) (Figure 5a ). Each mutant was tagged with a FLAG epitope sequence at its C-terminal. Immunoprecipitation followed by Western blotting was performed after co-transfection of each deletion mutant of Bcl10 and full-length cIAP2 into 293T cells. All constructs except C143 were coimmunoprecipitated with Bcl10 ( Figure 5b ). This result indicates that the binding site of Bcl10 to cIAP2 could be within amino acids 117 ± 143.
To understand the mechanisms of Bcl10 induced apoptosis, we tried to determine the essential domains of Bcl10 for induction of apoptosis. Morphological changes and caspase-3 like activities in 293T cells which were transiently co-transfected with each Bcl10 construct and GFP cDNA were examined. The great majority of GFP-positive cells, which were co-transfected with expression plasmids for Bcl10 and GFP, showed morphological characteristics of early stage of apoptosis such as shrinking cell bodies (Figure 6a) . Activation of caspase-3 like proteases was also observed in these cells (Figure 6b ). The same abilities were observed in cells transfected with C191 and N48. The eects of the transfection with N117 on induction of apoptosis were less than those of full-length, C191 or N48. Cells transfected with C143 showed no changes in morphology and caspase-3 like activities. These results indicate the domains of amino acids 117 ± 143, which predicted to be the binding site for cIAP2, are essential for activation of apoptosis signaling by Bcl10.
Discussion
The mutation of Bcl10 is commonly considered to be involved in the pathogenesis of a wide range of human malignancies. Therefore, it has been proposed that Bcl10 is a tumor suppressor gene. Overexpression of wild-type Bcl10 induces apoptosis in several types of cells (Thome et al., 1999; Koseki et al., 1999; . Indeed, our recent report showed that Bcl10 transgenic mouse revealed promotion of apoptosis in the thymocytes and lymphocytes at postnatal stages. These aspects raise the possibility that it could play crucial roles in regulation of apoptosis in various cells. In this report, to elucidate the regulatory mechanisms of apoptosis by Bcl10, we analysed biological characteristics of Bcl10, particularly focusing on the interchangeable interactions with the other apoptosis regulators, TRAF2 and cIAP2, during apoptosis.
Although Bcl10 has been known to interact with TRAF2 and cIAP2, the binding was demonstrated in this study to be dynamically interchangeable under apoptotic or non-apoptotic conditions. The changes of the binding partners of Bcl10 were closely associated with the promotion of apoptosis. That is, when apoptosis is undergone by overexpression of Bcl10, it preferentially interacts with cIAP2 and dissociates from TRAF2. Alternatively, when the apoptosis is suppressed by agents which decrease levels of phosphorylated-Bcl10, it forms a stable complex with TRAF2. The ®ndings indicate that Bcl10 is a mediator of apoptosis signaling by switching binding to cIAP2 from TRAF2. Indeed, the mutant which had the deleted binding site of Bcl10 for cIAP2, could not induce apoptosis even if the construct was overexpressed. It has been reported that BIR domains of cIAPs are capable of binding to caspase-3, -7, -9 and potentially inhibiting the activation of these caspases (Takahashi et al., 1998; Roy et al., 1997) . Therefore, we propose a possible mechanism of Bcl10-mediated apoptosis as follows; in cells in which apoptosis is induced by overexpression of Bcl10, or promoted by phosphorylation of Bcl10, Bcl10 causes competitive inhibition of the direct interaction of caspases and cIAPs. The dissociated caspases from cIAPs may result in the cleaving of substrates and lead the cells to apoptosis. Previously, we reported that the transgenic mice expressing Bcl10 exhibited abnormalities in their immune systems; that is, accelerated apoptosis in thymocytes and lymphocytes after the postnatal stage. This phenotype is similar to that of TRAF2-de®cient mice (Yeh et al., 1997) , suggesting that these two proteins might play crucial roles in the regulation of survival or cell death in immune systems in response to a number of cytokines. Additionally, as cIAP2 is abundantly expressed in lymphoid tissues, it also may be involved in regulation of apoptosis by co-operating with TRAF2 and Bcl10.
The phosphorylation of Bcl10 caused changes in its binding partners, suggesting that the switching of the binding partner is regulated by its phosphorylation. The putative phosphorylation sites serve the motifs that are phosphorylated by PKC and casein kinase 2. As the agents which regulate activities of PKC, such as PMA or H-7, caused alteration of the levels of phosphorylated-Bcl10, Bcl10 could be directly phosphorylated by PKC. A variety of reports have suggested that PKC can act as a potentiator of apoptosis induced by stimuli such as TNF (Laouar et al., 1999; Takada et al., 1999) . It is possible that Bcl10 might be a novel target molecule involved in the signaling of PKC-mediated apoptosis. The speculation is supported by the ®ndings that the accelerated phosphorylation of endogenous Bcl10 was observed in thymocytes initiating apoptosis after treatment with PMA. However, some other agents that modulate phosphorylation, dierently from the PKC pathways, also aected the levels of phosphorylated-Bcl10. Therefore, to clarify whether PKC directly phosphorylates Bcl10, further examination is needed.
As shown by the present study, Bcl10 interchangeably binds to TRAF2 and cIAPs through the events of Bcl10 phosphorylation, and the resultant alteration of its binding partner may activate apoptosis signaling. Therefore, regulatory controls of Bcl10 phosphorylation are possible strategies for therapies for some kinds of human cancers in the immune system.
Materials and methods
Cell culture and transfections
293T cells were cultured in Dulbecco's Modi®ed Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, penicilin (100 units/ml), streptomycin (100 mg/ml). Transient transfections into 293T cells were undertaken by Lipofect-AMINE reagent (Gibco BRL), according to the manufac- turer's procedures. To alter phosphorylation of Bcl10, 293T cells were treated with 10 nM PMA (SIGMA), 1 mM H-7 and H-89 (Seikagaku Kogyo, Tokyo, Japan), 10 mM Forskolin (SIGMA) and 1 mM Wortomaninn (SIGMA). Thymocytes were obtained from Wistar rat purchased from Nippon Charles River (Yokohama, Japan) and were suspended in RPMI supplemented with 10% fetal bovine serum.
Antibodies, immunoprecipitation and Western blotting
Rabbit antisera were raised against a synthetic peptide corresponding to residues 220 ± 233 of Bcl10. Anti-TRAF2 H-249 (Santa Cruz Biotechnology) and cIAP2 (Santa Cruz Biotechnology) polyclonal antibodies and Anti-Flag monoclonal antibody (Eastman Kodak) were purchased. For immunoprecipitation, cells were lysed in Nonidet P-40 buer (0.05 M Tris, pH 7.6, 0.15 M NaCl, 1 mM PMSF, 0.2% Nonidet P-40). Samples were incubated for 1 h at 48C with 3 mg antibody. Recombinant protein-G-agarose (GIBCO) was added to each of the samples, which were then incubated further for 1 h at 48C. The beads were washed ®ve times in lysis buer then boiled in SDS sample buer and loaded in 12% SDS-polyacrilamide gel. After electrophoresis, proteins were transferred to Immobilion-P membrane and immunodetection was done using an ECL Western blotting detection system (Amersham).
P-Orthophosphate labeling
For in vivo metabolic labeling assay, 293T cells were incubated in phosphate-free DMEM for 30 min before labeling. 150 mCi/ml 32 P-orthophosphate (NEN Life Science Products) was added to medium and incubated for approximately 3 h at 378C. Cells were then washed two times with Dulbecco's phosphate-buer saline and lysed in Nonidet P-40 lysing buer (0.05 M Tris, pH 7.6, 0.15 M NaCl, 1 mM PMSF, 0.2% Nonidet P-40). Radiolabeled lysate from each sample was immunoprecipitated with anti-Bcl10 antibody. The immunoprecipitated complexes were washed ®ve times in wash buer (same as lysis buer) then boiled in SDS sample buer and electrophoresed in 12% SDSpolyacrilamide gel. For detection of 32 P, the gel was dried and then exposed to X-ray ®lm.
Caspase-3 assay
293T cells transfected with Bcl10 or its mutant expression vectors were lysed in a lysis buer (50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 10 mM EGTA, 10 mM digitonin, 10 mM dithiothreitol). Caspase-3 activities in cell lysates were assayed with¯uorogenic substrate Ac-DEVD-AMC (Peptide Institute). Aliquots of 40 mg total proteins were incubated for 30 min at 378C in the presence of 0.1 mg of substrate.
Cleavage of Ac-DEVD-AMC was then measured using a luminescence spectrometer.
Detection of DNA fragmentation
Thymocytes were cultured with or without PMA in serum free RPMI for 12 h at 378C. Then thymocyte DNA were puri®ed using an Apoptotic DNA-Ladder Kit (Roche, USA). Aliquots of 2 mg DNA were electrophoresed in 1.5% agarose gel.
Construction of Bcl10 mutants
Wild-type Bcl10 expression vector has been described previously (Yoneda et al., 2000) . Deletion mutants were ampli®ed by PCR using the following oligos; For the carboxiterminal deletion mutants C143 (1 ± 143 amino acids), 5'-TCACTGATGTTCCTGCTGCTACTGTTCGAAGTTGCT-CTCATCAGAATT-3'; C191 (1 ± 191 amino acids), 5'-TCACTGATGTTCCTGCTGCTACTGTTCAAGCGAGG-CTGAAGAGAAGCT-3' as a sense and for the antisense, 5'-CCACCATGGAGGCTCCCGCGCCGTCT-3'. For the amino-terminal deletion mutant; N48 (48 ± 233 amino acids), 5'-CCACCATGAGTAGAGAAGACACAGAA-3'; N78 (78 ± 233 amino acids), 5'-CCACCATGCTGGACACCCTTGTG-GAA-3'; N117 (117 ± 233 amino acids), 5'-CCACCATGCT-GAAGTGCAGTAGCTGTGAG-3' as an antisense and for the sense, 5'-TCACTGATGTTCCTGCTGCTACTGTTC-CTGCCGTGAAAGAGCCC-3'. The sequence coding Flagepitope was tagged with each construct at its 3'-site and was subcloned into the EcoRI site of pcDNA3.1 vector.
Morphological evaluation of apoptosis
For morphological evaluation of cell death, a Live/Dead staining kit (Molecular Probes) was used. For apoptosis assay of deletion mutants, 293T cells were transfected with pairs of expression plasmids encoding Bcl10 or its mutants and GFP at a 1 : 10 ratio of GFP plasmid to Bcl10 plasmid. Fluorescence activity of GFP was viewed 48 h after transfection in a Nikon Diaphoto microscope equipped with epi¯uorescence. Fluorescence experiments were repeated on six occasions. Representative photomicrographs were shown.
